Balboa Biosciences Inc. is a dynamic clinical stage specialty biopharmaceutical company based in San Diego, California that in-licenses and develops both novel and well-known therapeutics for the treatment of Central Nervous System disorders and acute and chronic pain.

Balboa launched operations in October 2006 and is leveraging its development resources to develop and commercialize its leading CNS product candidates, BB01 and BB03 for the treatment of acute and chronic pain and BB02 a novel neuroprotective agent.

Balboa's seasoned and hands-on executive team have extensive experience in the development and commercialization of CNS therapeutics from the Big Pharma and Biotech environments.